Woebot Health, maker of an AI-powered mental health chatbot, announced it signed a three-year agreement with Ohio-based nonprofit pediatric healthcare system Akron Children's to provide pediatric mental health support to adolescents 13 to 17 years.
Woebot's nonprescription digital mental health tool includes content specific to teens, including media literacy, bullying in school settings, and...
After nearly 25 years at Kaiser Permanente, Trina Histon recently took on a new challenge at Woebot Health, the company behind a chatbot for mental healthcare.
Histon's new role as vice president of clinical product strategy will focus on integrating Woebot into clinical care. She previously spent several years at Kaiser developing a process to get digital mental health apps from clinicians into...
Woebot Health, maker of a mental health chatbot, recently appointed Dr. Robbert Zusterzeel as vice president of regulatory science and strategy.
Zusterzeel comes to Woebot from IQVIA, where he served as senior director of U.S. regulatory science and strategy. He'd previously worked at the FDA for nearly 10 years.
"We believe in and have embraced regulation from the start and have expanded our...
Digital musculoskeletal care company Hinge Health has hired Mario Queiroz as chief product officer.
Queiroz comes to Hinge from cybersecurity firm Palo Alto Networks, where he served as vice president of special projects. He also worked at Google for 14 years and held leadership positions at HP.
"Millions of Americans experience chronic back and joint pain. As someone deeply passionate about...
Woebot Health, maker of an AI-powered mental health chatbot, announced Tuesday it has raised $9.5 million from Leaps by Bayer.
The strategic investment comes about eight months after the company said it had scored $90 million in Series C funding. Last year, Woebot received FDA Breakthrough Device Designation for its digital therapeutic treating postpartum depression.
"Woebot Health’s mission and...
A digital chatbot could be one way to help individuals with substance abuse disorder, according to a new study published in Drug and Alcohol Dependence.
The study, which was conducted during the COVID-19 pandemic, found that individuals with SUD using the chatbot Woebot significantly reduced their substance use occasions more than individuals on the waitlist, who did not receive the intervention...
Digital mental health company Woebot Health has landed FDA Breakthrough Device Designation for its postpartum depression digital therapeutic, WB001.
WB001 combines cognitive behavioral therapy and elements of interpersonal psychotherapy with the company’s conversational chatbot, Woebot, to deliver treatment directly through patients’ phones.
Designed as a prescription digital therapeutic, the...
The emergence of digital mental health interventions has given traditional modes of treatment the ability to be highly scaled for use whenever and wherever the patient chooses.
These capabilities pose several advantageous characteristics to in-person therapy, but critics of these technology-based platforms continue to raise concerns over something they lack: a human connection between the...
A recent study published in the Journal of Medical Internet Research (JMIR) shows initial support for a new version of Woebot – a text-based chatbot app designed to address mental health issues – that is designed to reduce substance use and other measures tied to substance use disorder (SUD).
Conducted by researchers from Stanford University School of Medicine and Woebot Health, the investigation...
From virtual therapy to mindfulness and meditation aids, there’s little shortage of digital tools catching investors’ eyes and breaking into the crowded behavioral health market. Although a number of these services are positioning their business to focus on payers and employers, many others are taking their products directly to consumers via monthly subscriptions, one-time retail purchases or...
